New Delhi: Bharat Biotech’s coronavirus vaccine Covaxin has been found to be well-tolerated and produced an immune response, says the Phase-1 interim data published by the company in the peer-reviewed British medical journal Lancet, MoneyControl reported.
In Phase-1, potential vaccines are tested on healthy human volunteers to check for the safety or potential side-effects of the vaccine and the immunogenicity, or the immune response that enables the body to fight an infection.
Covaxin has been developed by the Hyderabad-based biotechnology firm in collaboration with the Indian Council of Medical Research and the National Institute of Virology. The vaccine is now undergoing phase-3 trials. Phase 2 trials are being analysed.
Other facts
The most common adverse event was pain at the injection site followed by headache, fatigue, and fever, the study said, according to MoneyControl.
Puri: The cutting of logs for construction of the three chariots for the annual Rath…
New Delhi: Versatile Bollywood actress Alia Bhatt and Olympic medal-winning wrestler Sakshi Malik have been named…
Kochi: Kerala Police have registered a case against two female foreign tourists for destroying pro-Palestine…
Bhubaneswar: Bharatiya Janata Party (BJP) moved Odisha’s Chief Electoral Officer (CEO) accusing the ruling Biju…
New Delhi: Developing vaccines to prevent fatal diseases can take years. Fortunately, the first vaccine…
Sundargarh: Two participants of a bike rally held on the occasion of Ram Navami were…
Mumbai: Boney Kapoor experienced several ups and downs before establishing himself as a leading producer…
Bhubaneswar: A passenger, who was allegedly smuggling gold, was caught by Customs officials at the…